v3.26.3
Segment (Tables)
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Summary of Reconciles Reported Revenues to Net (Loss) Income under Significant Expense Principle The following table reconciles reported revenues to net loss under the significant expense principle for the three and nine months ended September 30, 2026 and 2025 (in thousands):

 

 

For the Three Months
Ended September 30,

 

 

For the Nine Months
Ended September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Collaboration revenue

 

$

—

 

 

$

—

 

 

$

20,000

 

 

$

—

 

Research and development:

 

 

 

 

 

 

 

 

 

 

 

 

RAP-219 program external expenses

 

 

17,481

 

 

 

8,733

 

 

 

67,390

 

 

 

26,381

 

Preclinical programs external expenses

 

 

4,473

 

 

 

4,474

 

 

 

13,632

 

 

 

12,442

 

R&D personnel-related costs (including stock-based
   compensation)

 

 

10,559

 

 

 

7,381

 

 

 

31,836

 

 

 

20,833

 

 Other costs

 

 

1,803

 

 

 

1,691

 

 

 

5,588

 

 

 

4,875

 

Selling, general and administrative:

 

 

 

 

 

 

 

 

 

 

 

 

G&A personnel-related costs (including stock-based
   compensation)

 

 

7,486

 

 

 

5,487

 

 

 

21,554

 

 

 

15,491

 

Professional and consulting costs

 

 

1,459

 

 

 

1,322

 

 

 

6,594

 

 

 

3,906

 

Facility related and other

 

 

825

 

 

 

898

 

 

 

2,513

 

 

 

2,662

 

Loss from operations

 

$

(44,086

)

 

$

(29,986

)

 

$

(129,107

)

 

$

(86,590

)

Interest income

 

 

3,851

 

 

 

3,061

 

 

 

12,400

 

 

 

8,870

 

Net loss

 

$

(40,235

)

 

$

(26,925

)

 

$

(116,707

)

 

$

(77,720

)